Molecular and Clinical Heterogeneity within MYC-Family Amplified Medulloblastoma is Associated with Survival Outcomes: A Multicenter Cohort Study

Medicine, Neurology, Neurosurgery, Oncology,
medulloblastoma   MYC amplification   clinical heterogeneity   molecular subgroups   survival outcomes   high-risk disease   treatment strategies  

Clinical and Biological Heterogeneity in MYC/MYCN-Amplified Medulloblastoma Academic Background Medulloblastoma (MB) is one of the most common malignant brain tumors in children. Despite recent advances in treatment, approximately 30% of patients still die from the disease, and survivors often face long-term treatment-related complications. Amplifi...